This International Women’s Day, let’s take a moment to recognize and celebrate women in all aspects of pulmonary hypertension research: women who agree to participate in clinical trials, women who are researchers, and women who are on health care teams at clinics where research takes place. In the past, it wasn’t unusual for women to be left out of clinical trials, particularly women of childbearing age. Because women were excluded from research studies, we don’t fully understand how some...

March is National Nutrition month, and again the Dietitians of Canada have chosen Nourish to Flourish  as the theme, highlighting “highlights the profound connections between food and overall well-being, emphasizing the transformative role of nutrition in our lives”. It’s a good reminder that the everyday choices we make around food can have a big impact on how we feel. Nutrition can be top of mind for people with pulmonary hypertension, who often need to keep a low-sodium diet or to limit...

Two companies have announced the results of clinical trials of drugs for pulmonary arterial hypertension recently, neatly illustrating successful and unsuccessful results. Last week, Gossamer Bio announced that their drug, seralutinib, failed to meet the primary endpoint of its phase 3 PROSERA clinical trial . Gossamer’s stock price dropped precipitously. Interestingly, one of the reasons the study failed may have been an unusually good response to the placebo in some locations, and not a...